The purpose of this study was both to investigate whether polyp reduction or shrinkage affects the outcomes of patients with residual polyps after the loading phase of anti-VEGF therapy and to explore whether the percentage change of the polyp area could be a novel prognostic factor, which has not been reported in previous studies. The gene discussed is VEGFA; the disease is polyp.